One advantage of this study design, however, is that this trial will allow us to assess the benefit of AFP performed in addition to US or MRI in HCC surveillance, by examining the proportion of cases where early-stage HCC is detected by AFP elevation with negative US or MRI results. The gene discussed is AFP; the disease is hepatocellular carcinoma.